|
Q4 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Mar 31, 2024
|
|
|---|---|---|---|
| Current assets | |||
| Cash and cash equivalents | |||
| Restricted cash | |||
| Other receivables | |||
| Prepaids | |||
| Loan receivable | |||
| Prepaid expense | |||
| Total current assets | |||
| Non-current assets | |||
| Digital Assets | |||
| Equipment | |||
| Investment in Associate | |||
| Investment in Psyence Labs Ltd | |||
| TOTAL ASSETS | |||
| Current liabilities | |||
| Accounts payable and accrued liabilities | |||
| Convertible note liability | |||
| Due to related party | |||
| NCAC Sponsor | |||
| Psyence Group Inc | |||
| Derivative warrant liabilities | |||
| TOTAL LIABILITIES | |||
| SHAREHOLDERS’ EQUITY | |||
| Share Capital | |||
| Warrants Reserve | |||
| Options Reserve | |||
| Accumulated Deficit | |||
| Reserves | |||
| TOTAL SHAREHOLDERS’ EQUITY | |||
| TOTAL LIABILITIES AND SHAREHOLDERS EQUITY |
Loading...
